From Name:
From Email:
To Name:
To Email:

Optional Message:


Novartis' Promacta Gets FDA Breakthrough Designation For Severe Aplastic Anemia

from 01/05/18, Pharmaceutical Business Review

Novartis’ drug Promacta (eltrombopag) has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for first-line treatment of severe aplastic anemia (SAA). Promacta can now be used in combination with standard immunosuppressive therapy to treat the rare blood disorder. SAA is a condition in which the bone marrow of the patient cannot produce sufficient red blood cells, white blood cells and platelets. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063